Trending...
- Chicago: Mayor Brandon Johnson and CDPH Commissioner Ige Statement On Trump Cutting Billions In Mental Health And Addiction Services Funding
- Chicago: Mayor Brandon Johnson Statement On Trump Revoking Protected Status For Somali Immigrants
- Naperville Police Arrest Two Teens Charged with Sexually Assaulting a Female
SAN FRANCISCO - illiNews -- OKAVA Pharmaceuticals is a clinical-stage company developing medicines to enable dogs and cats to live longer, healthier lives. Today, the company announced that the first cat has been successfully dosed in MEOW-1 (ManagEment of OverWeight cats with OKV-119), a landmark clinical study evaluating OKV-119, an investigational, first-in-class, ultra-long-acting GLP-1 implant being developed specifically for weight management in cats. Beyond weight loss, the implications of this pet-tailored GLP-1 solution for diabetes, kidney disease, and healthy aging and longevity may be profound.
By improving cardiometabolic health through continuous delivery of a GLP-1 receptor agonist, OKV-119 has the potential to enhance quality of life, promote healthy aging, and become the most impactful life-extending therapy available for cats.
OKV-119 leverages the NanoPortal™ technology platform developed by Vivani Medical. The novel drug-delivery system is designed to provide smooth and steady delivery of therapeutic molecules, including GLP-1 receptor agonists, over extended periods from a single implant. This "One-and-Done" hassle-free solution is designed to guarantee that cats remain adherent for up to six months with a single implant administered during a routine office visit.
MEOW-1 marks the first-ever GLP-1 weight-loss clinical trial in cats or dogs, a landmark moment for veterinary medicine. In human medicine, GLP-1 receptor agonists have revolutionized the management of obesity, diabetes, and cardiometabolic health, becoming one of the most important therapeutic breakthroughs of the 21st century. OKAVA is now working to bring this same transformational class of medicines to dogs and cats, with an ultra-long-acting solution specifically engineered for safe and effective use in companion animals.
More on illi News
"Caloric restriction, or fasting, is one of the most well-established interventions for extending lifespan and improving metabolic health in cats," said Michael Klotsman, PhD, MBA, CEO of OKAVA. "But it's also one of the hardest to maintain. OKV-119 is designed to mimic many of the physiological effects of fasting — improved insulin sensitivity, reduced fat mass, and more efficient energy metabolism — without requiring significant changes in feeding routines or disrupting the human–animal bond that often centers around food."
The MEOW-1 study is being conducted under an FDA-CVM Investigational New Animal Drug (INAD) application and will evaluate the safety, tolerability, and weight-loss efficacy of OKV-119 in overweight or obese client-owned cats. Results from the study will inform future clinical development and regulatory filings and are expected to guide the initiation of similar studies in dogs. As part of its commitment to responsible, transparent clinical research, OKAVA has listed the MEOW-1 study in the American Veterinary Medical Association (AVMA) Clinical Trials Registry.
About OKV-119
OKV-119 is a miniature, subdermal exenatide implant designed to address the growing prevalence of obesity, diabetes and kidney disease in cats. The product utilizes Vivani Medical's NanoPortal™ technology platform. The implant can be inserted under the skin during a routine veterinary visit and is designed to deliver a steady dose of medication for up to six months.
OKV-119 is being developed by OKAVA in partnership with Vivani Medical under an exclusive veterinary licensing and collaboration agreement.
More on illi News
About OKAVA Pharmaceuticals
OKAVA is a clinical-stage research and development company that develops new treatment options for dogs and cats suffering from chronic diseases of aging. OKAVA is building a portfolio of products to transform and humanize standards of care in veterinary medicine. By harnessing breakthrough human technologies for the treatment of common diseases in household pets, the company has the potential to increase the lifespans of dogs and cats by an average of 1 to 3 years. OKAVA is a private company headquartered in San Francisco, California. For more information, see OKAVA.com.
About Vivani Medical
Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, see www.vivani.com.
For inquiries, contact:
Michael Klotsman
info@okava.com
415.818.1808
By improving cardiometabolic health through continuous delivery of a GLP-1 receptor agonist, OKV-119 has the potential to enhance quality of life, promote healthy aging, and become the most impactful life-extending therapy available for cats.
OKV-119 leverages the NanoPortal™ technology platform developed by Vivani Medical. The novel drug-delivery system is designed to provide smooth and steady delivery of therapeutic molecules, including GLP-1 receptor agonists, over extended periods from a single implant. This "One-and-Done" hassle-free solution is designed to guarantee that cats remain adherent for up to six months with a single implant administered during a routine office visit.
MEOW-1 marks the first-ever GLP-1 weight-loss clinical trial in cats or dogs, a landmark moment for veterinary medicine. In human medicine, GLP-1 receptor agonists have revolutionized the management of obesity, diabetes, and cardiometabolic health, becoming one of the most important therapeutic breakthroughs of the 21st century. OKAVA is now working to bring this same transformational class of medicines to dogs and cats, with an ultra-long-acting solution specifically engineered for safe and effective use in companion animals.
More on illi News
- Boston Industrial Solutions' BPA Certified BX Series Raises the Bar for Pad Printing Inks
- Nationwide Dog-Friendly Restaurant Directory Launches with 5,000+ Listings
- Boston Corporate Coach™ Sets Global Standard for Executive Chauffeur Services Across 680 Cities
- UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT
- Naperville Police Accepting Applications for Spring Citizen Police Academy
"Caloric restriction, or fasting, is one of the most well-established interventions for extending lifespan and improving metabolic health in cats," said Michael Klotsman, PhD, MBA, CEO of OKAVA. "But it's also one of the hardest to maintain. OKV-119 is designed to mimic many of the physiological effects of fasting — improved insulin sensitivity, reduced fat mass, and more efficient energy metabolism — without requiring significant changes in feeding routines or disrupting the human–animal bond that often centers around food."
The MEOW-1 study is being conducted under an FDA-CVM Investigational New Animal Drug (INAD) application and will evaluate the safety, tolerability, and weight-loss efficacy of OKV-119 in overweight or obese client-owned cats. Results from the study will inform future clinical development and regulatory filings and are expected to guide the initiation of similar studies in dogs. As part of its commitment to responsible, transparent clinical research, OKAVA has listed the MEOW-1 study in the American Veterinary Medical Association (AVMA) Clinical Trials Registry.
About OKV-119
OKV-119 is a miniature, subdermal exenatide implant designed to address the growing prevalence of obesity, diabetes and kidney disease in cats. The product utilizes Vivani Medical's NanoPortal™ technology platform. The implant can be inserted under the skin during a routine veterinary visit and is designed to deliver a steady dose of medication for up to six months.
OKV-119 is being developed by OKAVA in partnership with Vivani Medical under an exclusive veterinary licensing and collaboration agreement.
More on illi News
- Sharpe Automotive Redefines Local Car Care with "Transparency-First" Service Model in Santee
- Chicago: ICYMI: Mayor Brandon Johnson Builds On Community Safety, Violence, And Overdose Reduction Progress—Blasts Trump Cuts
- Indie Creator Opens the Digi 995 Universe Ahead of Kickstarter Launch
- Chicago: Mayor Brandon Johnson Announces New Record Of Nearly 13 Million Shared Bike And Scooter Trips In 2025
- Chicago: Mayor Brandon Johnson Announces Launch Of New Community Reentry Support Center For Women Returning From Incarceration
About OKAVA Pharmaceuticals
OKAVA is a clinical-stage research and development company that develops new treatment options for dogs and cats suffering from chronic diseases of aging. OKAVA is building a portfolio of products to transform and humanize standards of care in veterinary medicine. By harnessing breakthrough human technologies for the treatment of common diseases in household pets, the company has the potential to increase the lifespans of dogs and cats by an average of 1 to 3 years. OKAVA is a private company headquartered in San Francisco, California. For more information, see OKAVA.com.
About Vivani Medical
Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, see www.vivani.com.
For inquiries, contact:
Michael Klotsman
info@okava.com
415.818.1808
Source: OKAVA
0 Comments
Latest on illi News
- CryptaBox Introduces a Hardware Crypto Cold Storage Wallet
- YWWSDC Launches AI-Native Digital Asset Infrastructure, Merging Technical Innovation with US-Standard Compliance
- High-End Exterior House Painting in Boulder, Colorado
- Simpson and Reed Co-Founders Shardé Simpson, Esq. and Ciara Reed, Esq. Launch "Hello Wilma,"
- Naperville Police Arrest Two Teens Charged with Sexually Assaulting a Female
- Report Outlines Key Questions for Individuals Exploring Anxiety Treatment Options in Toronto
- Rande Vick Introduces Radical Value, Challenging How Brands Measure Long-Term Value
- Chicago: Mayor Brandon Johnson Statement On Trump Threatening To Halt Federal Funding For Sanctuary Cities
- Chicago: Mayor Brandon Johnson Statement On Trump Revoking Protected Status For Somali Immigrants
- Mayor Brandon Johnson And The Chicago Department Of Business Affairs And Consumer Protection Reaffirm Support For Small Business Community At The Start Of The New Year
- Lisa Mauretti Launches Peace of Mind Travel Coaching to Guide Fearful Travelers to Discover the World with Confidence
- New Year, New Home: Begin 2026 at Heritage at South Brunswick
- Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section
- Enders Capital: 25% Gains with Just -0.80% Maximum Monthly Drawdown in Volatile Debut Year 2025
- Chicago: Mayor's Office Of Reentry Releases Inaugural 2025 End Of Year Report
- CES Spotlight Highlights Need for Strategic Review as Throughput Demands Evolve
- ASR Media, Social T Marketing & PR Announce Merger
- $780,000 Project for New Middle East Police Service with Deposit Received and Preliminary Design Work Underway for Lamperd: Stock Symbol: LLLI
- The 3rd Annual Newark Summit for Real Estate, Economic Development & Placemaking Returns February 9th
- Digital Security Deposit Platform Whale Raises $4 Million Seed Round Led by Camber Creek